Real Life Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in Egypt - Trial NCT03510637
Access comprehensive clinical trial information for NCT03510637 through Pure Global AI's free database. This phase not specified trial is sponsored by ANRS, Emerging Infectious Diseases and is currently status unknown. The study focuses on Chronic Hepatitis C. Target enrollment is 7500 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
ANRS, Emerging Infectious Diseases
Timeline & Enrollment
N/A
Jan 22, 2018
Aug 01, 2020
Primary Outcome
Sustained Virological Response 12 weeks after the end of treatment (SVR12)
Summary
The primary purpose of the ANRS 12332 HepNile study cohort is to assess in Real-Life
 condition the efficacy and the safety profile of new Direct Acting Antivirals (DAAs)
 introduced in the Egyptian National Treatment Programme for the treatment of Chronic
 Hepatitis C (CHC).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03510637
Non-Device Trial